Esperion Therapeutics Overview

  • Founded
  • 1998

Founded
  • Status
  • Acquired/​Merged

  • Employees
  • 21

Employees
  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $5M

Esperion Therapeutics General Information

Description

Developer of pharmaceutical products for the treatment of cardiovascular and metabolic diseases. The company engages in research, development, and commercialization of oral, low-density lipoprotein cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • 46701 Commerce Center Drive
  • Suite B
  • Plymouth, MI 48170
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Esperion Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 28-Apr-2008 $5M 000 Completed Clinical Trials - Phase 2
5. Merger/Acquisition 01-Jan-2004 00.00 000.00 00.00 Completed Clinical Trials - Phase 2
4. IPO 09-Aug-2000 000.00 Completed Clinical Trials - Phase 2
3. Later Stage VC (Series C) 13-Jan-2000 0000 000.00 Completed Startup
2. Early Stage VC $6.2M Completed Startup
1. Debt - General 08-Nov-1999 $6.2M $6.2M Completed Startup
To view Esperion Therapeutics’s complete valuation and funding history, request access »

Esperion Therapeutics Executive Team (1)

Name Title Board Seat Contact Info
Roger Newton Ph.D Co-Founder, Executive Chairman, Board Member & Chief Scientific Officer
To view Esperion Therapeutics’s complete executive team members history, request access »

Esperion Therapeutics Board Members (2)

Name Representing Role Since
Roger Newton Ph.D Self Co-Founder, Executive Chairman, Board Member & Chief Scientific Officer 000 0000
You’re viewing 1 of 2 board members. Get the full list »

Esperion Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Esperion Therapeutics Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Canaan Partners Venture Capital Minority 000 0000 000000 0
HealthCap Venture Capital Minority 000 0000 000000 0
Oak Investment Partners Venture Capital Minority 000 0000 000000 0
Pfizer Corporation Minority 000 0000 000000 0
Scheer & Company Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »